X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1218) 1218
Book Review (254) 254
Newsletter (171) 171
Newspaper Article (48) 48
Publication (39) 39
Magazine Article (14) 14
Conference Proceeding (10) 10
Book Chapter (7) 7
Dissertation (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dapagliflozin (1395) 1395
type 2 diabetes (675) 675
index medicus (661) 661
glucose (526) 526
humans (513) 513
diabetes (502) 502
endocrinology & metabolism (407) 407
diabetes mellitus, type 2 - drug therapy (395) 395
double-blind (349) 349
dextrose (301) 301
sodium-glucose transporter 2 - antagonists & inhibitors (288) 288
canagliflozin (278) 278
male (273) 273
hypoglycemic agents - therapeutic use (271) 271
metformin (264) 264
insulin (252) 252
sglt2 inhibitor (248) 248
empagliflozin (237) 237
diabetes therapy (231) 231
female (231) 231
diabetes mellitus (230) 230
inadequate glycemic control (214) 214
glucosides - therapeutic use (210) 210
middle aged (206) 206
care and treatment (203) 203
pharmacology & pharmacy (201) 201
drug therapy (195) 195
analysis (194) 194
research (190) 190
glycemic control (173) 173
sodium (173) 173
mellitus (171) 171
sglt2 inhibitors (171) 171
animals (168) 168
hyperglycemia (166) 166
type 2 diabetes mellitus (165) 165
medical research (163) 163
safety (162) 162
hypoglycemic agents - adverse effects (156) 156
clinical trials (152) 152
efficacy (152) 152
benzhydryl compounds - therapeutic use (149) 149
medicine, experimental (149) 149
sglt2 (139) 139
treatment outcome (139) 139
risk factors (135) 135
type-2 diabetes-mellitus (134) 134
aged (132) 132
adult (131) 131
hypoglycemic agents (130) 130
hypoglycemic agents - pharmacology (127) 127
hypoglycemic agents - administration & dosage (124) 124
sodium-glucose transporter 2 - metabolism (122) 122
blood pressure (120) 120
dosage and administration (117) 117
glucosides - adverse effects (116) 116
glucosides - pharmacology (116) 116
diabetes mellitus, type 2 - blood (114) 114
blood glucose - metabolism (108) 108
glucosides - administration & dosage (107) 107
blood glucose - drug effects (105) 105
body weight (105) 105
hypoglycemia (105) 105
internal medicine (103) 103
diabetes mellitus, type 2 - metabolism (100) 100
double-blind method (95) 95
drug therapy, combination (95) 95
add-on (94) 94
medicine, general & internal (93) 93
glycosylated hemoglobin (90) 90
patients (90) 90
benzhydryl compounds - adverse effects (89) 89
medicine & public health (88) 88
add-on therapy (87) 87
heart failure (86) 86
blood-pressure (84) 84
benzhydryl compounds - administration & dosage (83) 83
cardiovascular diseases (83) 83
health aspects (83) 83
insulin resistance (82) 82
reports (81) 81
pharmaceutical industry (80) 80
benzhydryl compounds - pharmacology (78) 78
body-weight (78) 78
inhibitors (78) 78
metabolism (78) 78
glycated hemoglobin a - metabolism (75) 75
rats (75) 75
type-2 (75) 75
mortality (74) 74
complications and side effects (73) 73
endocrinology (73) 73
diabetes mellitus, type 2 - complications (72) 72
diabetics (72) 72
blood sugar (71) 71
risk (71) 71
glucose metabolism (70) 70
hypertension (70) 70
therapy (69) 69
glucose - metabolism (68) 68
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1393) 1393
German (21) 21
Spanish (19) 19
Czech (7) 7
French (5) 5
Korean (5) 5
Russian (4) 4
Japanese (3) 3
Chinese (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 09/2015, Volume 38, Issue 9, pp. 1638 - 1642
Journal Article
by Kim, KS
DIABETES & METABOLISM JOURNAL, ISSN 2233-6079, 06/2019, Volume 43, Issue 3, pp. 377 - 378
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
OBJECTIVE To assess the efficacy/safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, compared with glimepiride over 104 weeks in patients with... 
PLACEBO | ADD-ON | MONOTHERAPY | HYPERGLYCEMIA | SULFONYLUREA | EFFICACY | DAPAGLIFLOZIN | SAFETY | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | MELLITUS
Journal Article
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, ISSN 1567-567X, 10/2018, Volume 45, pp. S93 - S94
Conference Proceeding
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, ISSN 1178-7007, 03/2016, Volume 2016, Issue Issue 1, pp. 71 - 82
Stanley S Schwartz,1,2 Arie Katz3 1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort... 
dapagliflozin | combination therapy | metformin
Journal Article
American Journal of Hypertension, ISSN 0895-7061, 04/2019, Volume 32, Issue 5, pp. 452 - 459
Abstract BACKGROUND Dapagliflozin (DAPA) is an inhibitor of sodium-glucose cotransporter 2 prescribed for type 2 diabetes mellitus. DAPA plays a protective... 
Myocardial fibrosis | Dapagliflozin | TAC | Cardiac remodeling | Apoptosis | FoxO1 | Hypertrophy | MAPKs
Journal Article
WHO Drug Information, ISSN 1010-9609, 09/2018, Volume 32, Issue 4, p. 556
Journal Article
Obesity research & clinical practice, ISSN 1871-403X, 08/2019
Journal Article
Asian Journal of Pharmaceutical and Clinical Research, ISSN 0974-2441, 03/2017, Volume 10, Issue 3, pp. 406 - 408
Journal Article
Kardiologicka Revue, ISSN 1212-4540, 2018, Volume 20, Issue 1, pp. 61 - 65
Journal Article
Kardiologicka Revue, ISSN 1212-4540, 2016, Volume 18, Issue 2, pp. 119 - 124
Journal Article
AMERICAN JOURNAL OF KIDNEY DISEASES, ISSN 0272-6386, 09/2019, Volume 74, Issue 3, pp. 328 - 337
Rationale & Objective: Hyperglycemia exacerbates the progression of chronic kidney disease (CKD), but most glucose-lowering therapies do not address... 
DAPAGLIFLOZIN | EFFICACY | SGLT2 INHIBITORS | UROLOGY & NEPHROLOGY | RISK | PHARMACODYNAMICS | CHRONIC KIDNEY-DISEASE | BLOOD-GLUCOSE CONTROL | EMPAGLIFLOZIN
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 10/2019, Volume 860, pp. 172537 - 172537
The widely used db/db mouse as a model of diabetic nephropathy (DN) only mimics the early changes in human DN with a slow disease progression. Since high... 
Sodium glucose transporter 2 | Diabetic nephropathy | High protein diet | Hyperfiltration | Dapagliflozin | db/db mouse | Index Medicus
Journal Article
NEPHROLOGY DIALYSIS TRANSPLANTATION, ISSN 0931-0509, 07/2018, Volume 33, Issue 7, pp. 1280 - 1280
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 05/2019, Volume 7, Issue 5, pp. 328 - 329
Journal Article
Journal of Hypertension, ISSN 0263-6352, 07/2019, Volume 37 Suppl 1, pp. e157 - e157
OBJECTIVE:The combination of type 2 diabetes mellitus (DM-2) and arterial hypertension (AH) increases the risk of development of cardiovascular complications... 
PERIPHERAL VASCULAR DISEASE | Type 2 diabetes | Hypertension | Diagnosis | Drug therapy | Dapagliflozin | Testing
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2018, Volume 72, Issue 15, pp. 1845 - 1855
Patients with type 2 diabetes mellitus have an increased risk for the development of cardiac and other vascular events, heart failure (HF), and decline in... 
heart failure | renal function | diabetes | SGLT2 inhibitor | KIDNEY-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | DAPAGLIFLOZIN | SGLT2 INHIBITORS | HEART-FAILURE | RISK | DEATH | ESTABLISHED CARDIOVASCULAR-DISEASE | PHARMACOKINETICS | OUTCOMES | EMPAGLIFLOZIN
Journal Article